Table 1.
Demographics and TB characteristics.
| Total n:22 | RFM Group (n:12) | RFB Group (n:10) | p value |
| Median Age on TB Diagnosis (IQR): | 56 (8) | 58 (10) | 0.872 |
| Sex, n (%): | |||
| Male/Female | 9(75)/3(25) | 4(40)/6(60) | 0.192 |
| LDLT Indication, n (%): | |||
| HCC (+HBV/HCV/ALC) | 9 (75) | 7 (70) | 0.702 |
| HBV only | 1 (8.3) | 1 (10) | |
| HCV only | 1 (8.3) | 2 (20) | |
| HBV + ALC | 1 (8.3) | 0 | |
| Median MELD score (IQR): | 10 (5) | 14 (11) | 0.107 |
| Child-Pugh Class, n (%) | |||
| A | 6 (50) | 2 (20) | 0.104 |
| B | 4 (33) | 2 (20) | |
| C | 2 (17) | 6 (60) | |
| TB Location, n (%): | |||
| Pulmonary | 9 (75) | 7 (70) | 0.528 |
| Extra-Pulmonary | 0 | 1 (10) | |
| Disseminated | 4 (25) | 2 (20) | |
| Timing of TB Diagnosis, | |||
| n (%): | 0.391 | ||
| Pre-LDLT | 8 (67) | 4 (40) | |
| Post-LDLT | 4 (33) | 6 (60) | |
| Median Duration of TB Treatment (IQR): | 7 (3) months | 7.5 (3.5) months | 0.722 |
| Immunosuppressant used during TB Treatment,n (%): | |||
| Sirolimus based | 10 (83) | 3 (30) | 0.026 |
| Everolimus based | 0 | 3 (30) | |
| Tacrolimus based | 2 (17) | 4 (40) | |
Abbreviations: TB: tuberculosis; RFM: rifampicin; RFB: rifabutin; IQR: interquartile range; LDLT: living donor liver transplant; HCC: hepatocellular carcinoma; HBV: hepatitis B related liver cirrhosis; HCV: hepatitis C related liver cirrhosis; ALC: alcoholic liver cirrhosis.